Analysis of referrals after a synergic work between primary care and urology. Impact of joint protocol implementation and a continuing education program in our healthcare area

García‐Rojo, Esther; Medina-Polo, J.; Sopeña-Sutil, R.; Guerrero-Ramos, F.; García‐Gómez, Borja; Aguilar-Gisbert, L.; García-Álvarez, G.; Azcutia-Gómez, M.R.; Gómez-Martín, F.; Molero-García, J.M.; Pereda-Arregui, E.; Cabañero, M.C. Vargas-Machuca; Villacampa-Aubá, F.; Sánchez, Á. Tejido

doi:10.1016/j.acuroe.2019.03.008

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, as fewer patients treated by GPs vs urologists may receive adequate diagnostic evaluation and therapy, there remains a need for better training to recognise LUTS symptoms and educational programs for GPs to effectively treat patients with LUTS 26‐28 . In this regard, a program developed in Spain that included the establishment of diagnostic protocols and referral practices, as well as continuous training measures and cooperation between GPs and urologists with periodic evaluation of the outcomes and measures, resulted in positive outcomes with a reduction in the number of referrals for LUTS and improved referral adequacy from 46% to 65% 29 …”

Section: Discussionmentioning

confidence: 99%

A retrospective analysis comparing persistence and adherence to treatment with free‐ vs fixed‐dose combination of an alpha blocker and an antimuscarinic agent in men with LUTS in Spain

Landeira¹,

Blázquez²,

Almeida

et al. 2020

Int. J. Clin. Pract.

View full text Add to dashboard Cite

Introduction: Combination therapy with an alpha blocker (AB) plus an antimuscarinic (AM) is recommended for men with moderate-to-severe mixed lower urinary tract symptoms (LUTS) when monotherapy is not effective in relieving storage symptoms. This study compared treatment persistence and adherence with an AB plus AM fixed-dose combination (FDC) vs an AB plus AM free-dose combination in men with LUTS in Spain. Methods: Retrospective study using the Spanish IQVIA Cegedim Electronic Medical Records database. Men prescribed AB plus AM combination therapy were included in an FDC or free-dose combination cohort based on their index treatment. Treatment persistence was the time from index date to first discontinuation of ≥1 of the two index drugs over 12 months. Adherence was measured using the fixed medication possession ratio (MPR). Results: Of 3114 patients identified, 999 were included (FDC, n = 790; free-dose combination, n = 209). Median (95% CI) persistence was longer in the FDC (125 [109-151] days) than in the free-dose combination (31 [31-36] days) cohort (hazard ratio [HR], 2.9; 95% CI, 2.4-3.4; P < .0001). The 12-month persistence rates were 31.1% (FDC cohort) and 8.9% (free-dose cohort). The mean (SD) fixed MPR was higher in the FDC cohort (48.8 [37.2]) compared with the free-dose cohort (23.1 [28.4]); more patients in the FDC cohort (34.2%) than in the free-dose cohort (10.

show abstract

Section: Discussionmentioning

confidence: 99%